Previous 10 | Next 10 |
2023-11-09 08:45:53 ET Palm Beach, FL – November 9, 2023 – FinancialNewsMedia.com News Commentary – According to the American Cancer Society projections, there were around 9,440 new instances (3,150 in men and 6,290 in women) and about 1,670 fatalities (930 ...
Oncolytics Announces the Anal Cancer Cohort of the GOBLET Phase 1/2 Study of Pelareorep and Atezolizumab Has Met the Success Criteria for Efficacy Canada NewsWire Pelareorep-atezolizumab combination data exceeds historical control trials with a 37.5% objective response rate, i...
Oncolytics Provides Update on Pancreatic Cancer Program for Pelareorep Canada NewsWire Updated plan follows PanCAN's strategic re-evaluation of the Precision Promise SM Program PanCAN US$5 million grant provides support for new GOBLET mFOLFIRINOX arm to proceed...
2023-11-03 21:05:19 ET Oncolytics Biotech Inc. (ONCY) Q3 2023 Earnings Conference Call November 3, 2023 08:30 AM ET Company Participants Jon Patton - Director, IR Matt Coffey - President & CEO Thomas Heineman - Chief Medical Officer Andrew de Guttadauro -...
Oncolytics Biotech® and SOLTI Present Further Positive Pelareorep Translational Data at SITC Canada NewsWire Novel imaging mass cytometry (IMC) technology enables a closer look at tumor microenvironment post-pelareorep/atezolizumab/letrozole treatment Affirms pe...
2023-11-03 07:09:19 ET More on Oncolytics Biotech Oncolytics Biotech: Is The Early Data Really That Good? Oncolytics Biotech Inc. (ONCY) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Oncolytics Biotech Historical earnings data for On...
HST Global Inc (HSTC) is expected to report for quarter end 2023-09-30 Air China Ltd ADR - Level I (AIRYY) is expected to report for Q3 2023 GrafTech International Ltd. (EAF) is expected to report $-0.05 for Q3 2023 Cardinal Health Inc. (CAH) is expected to report $1.4 for Q1 2024 ...
Oncolytics Biotech® Reports Third Quarter 2023 Financial Results and Operational Highlights Canada NewsWire Phase 1/2 survival data from GOBLET pancreatic cancer cohort demonstrates improvements over historical control trials Award and grant funding from Pancreati...
Oncolytics Biotech Inc. (ONCY) is expected to report $-0.07 for Q3 2023
2023-10-23 09:45:50 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – October 23, 2023 – USA News Group – Despite being a relatively rare form of cancer, pancreatic cancer remains one of the deadliest in the onco...
News, Short Squeeze, Breakout and More Instantly...
Oncolytics Biotech Inc. Company Name:
ONCY Stock Symbol:
NASDAQ Market:
Oncolytics Biotech Inc. Website:
Oncolytics Biotech® Announces Productive FDA Type C Meeting on its Metastatic Breast Cancer Program Canada NewsWire Clear path forward on key elements of the planned potential registration-enabling trial in HR+/HER2- metastatic breast cancer On track to report ove...
Oncolytics Biotech® Announces President and Chief Executive Officer Dr. Matt Coffey to Take Medical Leave of Absence Canada NewsWire Wayne Pisano , Chair of Oncolytics' Board of Directors, to serve as interim CEO Overall Survival data from BRACELET-1 breast ca...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...